Semintra 4 mg/ml Oral Solution for Cats

The safety and efficacy of telmisartan for the management of systemic
hypertension above 200 mmHg has not been investigated.

i). Special precautions for use in animals
The safety and efficacy of telmisartan has not been tested in cats under the age
of 6 months.
It is good clinical practice to monitor the blood pressure of cats receiving the
veterinary medicinal product which are under anaesthesia.
Due to the mode of action of the veterinary medicinal product, transient
hypotension may occur. Symptomatic treatment, e.g. fluid therapy, should be
provided in case of any clinical signs of hypotension. The dosage of telmisartan
should be reduced if systolic blood pressure (SBP) is consistently lower than
120 mmHg or if there are concurrent signs of hypotension.
As known from substances acting on the Renin-Angiotensin-Aldosterone
System (RAAS), a slight decrease in red blood cell count may occur. Red blood
cell count should be monitored during therapy.
Substances acting on the RAAS may lead to a reduction in glomerular filtration
rate and worsening renal function in cats with severe kidney disease. The
safety and efficacy of telmisartan in such patients has not been investigated.
When using this product in cats with severe kidney disease, it is advisable to
monitor renal function (plasma creatinine concentration).
In cats with hypertension it is good clinical practice to regularly monitor blood
pressure.
ii). Special precautions to be taken by the person administering the veterinary
medicinal product to animals
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet or the label to the physician.
Avoid eye contact. In case of accidental eye contact, rinse eyes with water.
Wash hands after use.
Pregnant women should take special care to avoid contact with the product
because substances acting on the RAAS, such as Angiotensin Receptor
Blockers (ARBs) and ACE inhibitors (ACEis), have been found to affect the
unborn child during pregnancy in humans.
People with hypersensitivity to telmisartan or other sartans/ARBs should avoid
contact with the veterinary medicinal product.

Issued: July 2023
AN:01478/2022
iii) Special precautions for the protection of the environment
Not applicable.